Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS4 | Q9NRS4 | 3/20 | 0.51 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 3/20 | 0.38 |
| ▸ | F10 | P00742 | 3/20 | 0.38 |
| ▸ | PLAU | P00749 | 3/20 | 0.38 |
| ▸ | PLAT | P00750 | 3/20 | 0.38 |
| ▸ | CXCR2 | P25025 | 3/20 | 0.37 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.37 |
| ▸ | HNF4A | P41235 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.36 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9372371 | 0.79 | TMPRSS4 (0.49) | TMPRSS4P2RX1CXCR2CXCR1HNF4A | |
| SCHEMBL21884470 | 0.78 | KMT2A (0.40) | TMPRSS4F2F10PLAUPLAT | |
| SCHEMBL21884388 | 0.77 | TMPRSS4 (0.47) | TMPRSS4P2RX1LRRK2CYSLTR2CYSLTR1 | |
| SCHEMBL21884407 | 0.77 | NPC1 (0.51) | TMPRSS4P2RX1 | |
| SCHEMBL21884511 | 0.77 | TMPRSS4 (0.44) | TMPRSS4P2RX1 | |
| SCHEMBL21884625 | 0.77 | ACLY (0.47) | TMPRSS4P2RX1F2F10PLAU | |
| SCHEMBL23875335 | 0.76 | P2RX1 (0.57) | TMPRSS4P2RX1 | |
| SCHEMBL21884644 | 0.76 | PPIA (0.50) | TMPRSS4P2RX1F2F10PLAU | |
| SCHEMBL21884653 | 0.76 | PLAU (0.61) | TMPRSS4F2F10PLAUPLAT | |
| SCHEMBL21884390 | 0.76 | TMPRSS4 (0.44) | TMPRSS4P2RX1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS INC. | 2021-12-02 | — | — | US | disclosed |
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS INC. | 2021-12-02 | — | — | US | disclosed |
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | JNANA THERAPEUTICS INC. | 2021-09-30 | — | — | US | disclosed |
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | JNANA THERAPEUTICS INC. | 2021-09-30 | — | — | US | disclosed |
| WO-2020061473-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | SLC19A1, SLC1A5, SLC1A2 | TMPRSS4 1380/4885P2RX1 3206/4885LRRK2 3750/4885 |
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | SNRPE, G3BP1, G3BP2 | TMPRSS4 3136/4885P2RX1 4811/4885LRRK2 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.